Short answer
TANDEM DIABETES CARE INC (TNDM) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $247M (up 5.5% year over year) with net income of −$20M.
Q1 2026 key financials · XBRL
- Revenue
- $247M
- +5.5% YoY
- Net income
- −$20M
- +84.4% YoY
- Operating margin
- -7.1%
- Gross margin
- 55.3%
- EPS (diluted)
- −$0.30
- +84.8% YoY
Source: XBRL data from the TANDEM DIABETES CARE INC (TNDM) Q1 2026 10-Q on SEC EDGAR. USD.
TANDEM DIABETES CARE INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Accumulated deficit $1.3 billion as of March 31, 2026, with continued operating losses and uncertain profitability timing
- CMS finalized competitive bidding and monthly rental reimbursement changes on December 2, 2025, potentially reducing rates and delaying pump sales recognition
- Pharmacy-channel reimbursement strategy may reduce upfront pump sales and gross profit before supply revenue offsets emerge
- GLP-1 adoption since 2023 has likely negatively affected the insulin therapy market
- CGM integration depends on Dexcom and Abbott agreements, which may terminate or face delays and disputes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TANDEM DIABETES CARE INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.